M.D. Sass Concentrated Value ETF (SASS)

The M.D. Sass Concentrated Value ETF, ticker SASS, is a disciplined but concentrated expression of deep-value investing: it holds a small number of large US companies that the fund’s advisers believe the market has mispriced downward, seeking to capture the returns that come when market sentiment shifts and prices revert toward fundamental worth.

“We are buying companies that the market has abandoned, at prices that embed pessimism about futures that may never arrive.”

The concentration thesis

SASS typically holds between 20 and 35 holdings, which makes it far more concentrated than a broad market index (which holds roughly 500 stocks) and even more concentrated than many “value” funds. The M.D. Sass advisers conduct bottom-up fundamental research on large US companies, focusing on those trading at what they consider deeply discounted valuations relative to earnings, cash flow, tangible assets, or dividend yield. The idea is that if you can identify a handful of fundamentally sound companies whose stocks have been beaten down by market indifference or temporary bad news, you can construct a small portfolio that captures substantial upside when sentiment improves or problems resolve.

This is not a strategy that seeks to time the market, but rather to identify overlooked value. The holdings are typically rebalanced annually or as the research conclusion changes, rather than daily or monthly. Turnover is moderate, and the portfolio’s composition reflects the advisers’ genuine beliefs about where value lies right now, not a mechanical formula.

What value investing actually requires

The value investor’s edge, if it exists, comes from research and patience: the willingness to hold something that the market dislikes while waiting for either the business situation to improve or the market’s assessment to change. SASS’s concentration amplifies this — with 25 holdings instead of 500, you are betting more heavily on your best ideas. The advantage is that 25 deeply researched stocks may outperform 500 passively held ones if your research is good and your patience is long. The disadvantage is that a single company in a concentrated portfolio can drag returns down significantly if the research conclusion proves wrong, and concentrated value funds can underperform for years if the market remains indifferent to the value thesis.

The true tailwind for a value strategy is a turn in sentiment or fundamentals — when the economy improves, when interest rates fall, when neglected sectors come back into favour. The true headwind is when the market remains convinced that the “cheap” stocks deserve to be cheap, or when the fundamental thesis breaks and the stock falls further.

Holdings and research process

SASS’s actual holdings reflect the advisers’ current conviction list — not a mechanical screen but a researched selection. The fact sheet and holdings reports show what they own and hint at the reasoning. The prospectus outlines the general approach; more detail appears in the fund’s reports or on the adviser’s website. Examining the composition reveals whether SASS is value-focused on unpopular sectors (energy, financials, industrials) or across the market, and whether the holdings are truly “cheap” by traditional metrics (price-to-book, price-to-earnings, dividend yield) or whether “cheap” means something more forward-looking in the adviser’s view.

Costs and turnover

The expense ratio is in the single-digit basis points, reasonable for active management. Turnover depends on how frequently the advisers’ research conclusions change; typical ranges are low to moderate, which keeps trading costs and tax drag manageable. Because the fund holds larger, more liquid companies, trading the positions does not impose market-impact costs.

The value investor’s patience test

SASS performs best when the market favours value — when defensive, cheaper stocks outperform growth at premium multiples. In extended periods of growth dominance (like the 2010s or the 2020–2023 period), concentrated value can lag substantially, which tests investors’ conviction. The prospectus and fact sheet show performance over one-year, three-year, five-year, and longer periods against both a broad market index and explicit value benchmarks. A fund that underperforms the market over five years but beats it over ten years suggests patience was rewarded; a fund that lags over both suggests either the research is not adding value or the strategy’s timing is simply unlucky.

Research should include reading the adviser’s commentaries on why the holdings are valuable and how long the thesis might take to play out. A value strategy that expects a thesis to resolve in two years and is still waiting after five raises questions. And remember that concentration means SASS is not a replacement for a diversified portfolio, but rather a satellite position for investors with conviction in value investing as a whole and trust in the adviser’s research.